Hypertension therapy and cardiovascular protection. Effects of angiotensin II receptor block with Valsartan

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 11, 2011, Pages 1247-1255

  Sestito, A ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

ACE inhibitors; Angiotensin receptor blockade; Cardiovascular diseases; Hypertension; Renin angiotensin system; Valsartan

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; PLACEBO; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; DRUG DOSE INCREASE; DRUG SAFETY; FOLLOW UP; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; MONOTHERAPY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; CARDIOVASCULAR DISEASE; DRUG COMBINATION; DRUG EFFECT; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; VALINE;

EID: 84855995787     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. MOCHIZUKI S, DAHLOF B, SHIMIZU M, IKEWAKI K, YOSHIKAWA M, TANIGUCHI I, OHTA M, YAMADA T, OGAWA K, KANAE K, KAWAI M, SEKI S, OKAZAKI F, TANIGUCHI M, YOSHIDA S, TAJIMA N, FOR THE JIKEI HEART STUDY GROUP. Valsartan in the Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study). A randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-1439. (Pubitemid 46635780)
2. BONOW RO, SMAHA LA, SMITH SC JR, MENSAH GA, LENFANT C.World Heart Day 2002. The international burden of cardiovascular disease. Responding to the emerging global epidemic. Circulation 2002; 106: 1602-1605.
3. SAWADA T, YAMADA H, DAHLOF B, MATSUBARA H, FOR THE KYOTO HEART STUDY GROUP. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks. KYOTO HEART Study. Eur Heart J 2009; 30: 2461-2469.
4. MAZZAGLIA G, AMBROSIONI E, ALACQUA M, FILIPPI A, SESSA E, IMMORDINO V, BORGHI C, BRIGNOLI O, CAPUTI AC, CRICELLI C, MANTOVANI LG. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120: 1598-1605.
5. EZZATI M, LOPEZ AD, RODGERS A, VANDER HOORN S, MURRAY CJ. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347-1360. (Pubitemid 35341298)
6. LAW M, WALD N, MORRIS J. Lowering blood pressure to prevent myocardial infarction and stroke. A new preventive strategy. Health Technol Assess 2003; 7: 1-94.
7. MANCIA G, DE BACKER G, DOMINICZAK A, CIFKOVA R, FAGARD R, GERMANO G, GRASSI G, HEAGERTY AM, KJELDSEN SE, NARKIEWICZ K, RUILOPE S, RYNKIEWICZ A, SCHMIEDER RE, BOUDIER HA, ZANCHETTI A, FOR THE ESH-ESC TASK FORCE ON THE MANAGEMENT OF ARTERIAL HYPERTENSION. 2007 ESH-ESC practice guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1751-1762.
8. WEIR MR, LEVY D, CRIKELAY N, ROCHA R, MENG X, GLAZER R. Time to achieve blood pressure goal. Influence of dose of valsartan monotherapy and valsartan and hydrochlothyazide combination therapy. Am J Hypertens 2007; 20: 807-815. (Pubitemid 46936176)
9. CHOBANIAN A, BAKRIS GL, BLACK HR, CUSHMAN WC, GREEN LA, IZZO JL JR, JONES DW, MATHERSON BJ, OPARIL S, WRIGHT JT JR, ROCCELLA EJ, NATIONAL HIGH BLOOD PRESSURE EDUCATION PROGRAM COORDINATING COMMITTEE. Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252. (Pubitemid 37553153)
10. RIDKER PM, DANIELSON E, RIFAI N, GLYNN RJ, FOR THE VAL-MARC INVESTIGATORS. Valsartan, blood pressure reduction, and C-reactive protein. Primary report of Val-MARC Trial. Hypertension 2006; 48: 1-7.
11. GASBARRINI G. "Trattato di Medicina Interna". Verduci Editore, Roma, 2011.
12. SIRAGY HM. Angiotensin receptor blockers. How important is selectivity? Am J Hypertens 2002; 15: 1006-1014. (Pubitemid 35217410)
13. ISRAILI ZH, HALL WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitors therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-242.
14. VERME-GIBBONEY C. Oral angiotensin-converting enzyme inhibitors. Am J Health Syst Pharm 1997; 54: 2689-2703.
15. JULIUS S, KJELDSEN SE, WEBER MA, BRUNNER HR, EKMAN, HANSON L, HUA TA, LARAGH J, MCINNES GT, MITCHELL L, PLAT F, SCHORK A, SMITH B, ZANCHETTI A, FOR THE TRIAL VALUE GROUP. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine. The VALUE randomized trial. Lancet 2004; 363: 2022-2031. (Pubitemid 38781102)
16. JULIUS S, WEBER MA, KJELDSEN SE, MCINNES GT, ZANCHETTI A, BRUNNER HR, LARAGH J, SCHORK A, HUA TA, AMERENA J, BALAZOVIECH, CASSEL G, HERCZEG B, KOYLAN N, MAGOMETSCHNIGG D, MAJAHALME S, MARTINEZ F, OIGMAN W, GOMEZ RS, ZHU J. The valsartan antihypertensive long-term use evaluation (VALUE) trial. Outcomes in patients receiving monotherapy. Hypertension 2006; 48: 385-391. (Pubitemid 44253730)
17. LACOURCIERE Y, WRIGHT JT JR, SAMUEL R, ZAPPE D, PURKAYASTHA D, BLACK HR AND ON THE BEHALF OF THE EVALUATE STUDY. Effects of forced-titrated valsartan/ hydrochlorothiazide versus amlodipine/ hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension. The EVALUATE Study. Blood Press Monit 2009; 14: 112-120.
18. COSTA FV, DEGLI ESPOSTI L, CERRA C, VERONESI C; BUDA S. Trends in prescription and determinants of persistence to antihypertensive therapy. The PAPEETE Study. High Blood Press Cardiovasc Prev 2009; 16: 167-176.
19. COHN JN, TOGNONI G, FOR THE VALSARTAN HEART FAILURE TRIAL INVESTIGATORS. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675. (Pubitemid 33126822)
20. HOLLENBERG NK, PARVING HH, VIBERTI G, REMUZZI G, RITTER S, ZELENKOFSKE S, KANDRA, DALEY WL, ROCHA R. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25: 1921-1926. (Pubitemid 47356634)
21. GAZIANO TA, BITTON A, ANAND S, WEINSTGEIN MC. The global cost of non optimal blood pressure. J Hypertens 2009; 27: 1472-1477.
22. HANSSON L, LLOYD A, ANDERSON P, KOPP Z. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press 2002; 11: 35-45. (Pubitemid 34257355)
23. FALASCHETTI E, CHAUDHURI M, MINDELL J, POULTER N. Continued improvement in hypertension management in England. Results from Health Survey for England 2006. Hypertension 2009; 53: 480-486.